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The intestinal epithelium harbors a large number of T cells, including TCRab cells that lack expression of CD4
and CD8ab coreceptors. In this issue of Immunity, Mayans et al. (2014) and McDonald et al. (2014) shed light
on the specificity and development of this enigmatic T cell population.Intestinal epithelial cells are interspersed
with numerous lymphocytes that make
up one of the largest populations of
T cells in the body. Positioned at a key
interface between the body and the
external environment, intestinal intraepi-
thelial lymphocytes (IELs) play critical
roles in host defense against pathogens,
but must also regulate immune responses
to prevent damage to the intestinal
epithelium and maintain tolerance in the
gut. Intestinal IELs include conventional
CD4 and CD8ab T cells, as well as a sig-
nificant population of unconventional
T cell types including gd T cells and
T cell receptor (TCR) TCRab coreceptor-
negative (or double-negative, DN) T cells
(Figure 1; Cheroutre et al., 2011). DN
TCRab IELs can represent up to a quarter
of total intestinal IELs; however, little is
understood regarding the development
and function of this unique T cell subset.
In this issue of Immunity, two reports
reveal the key role of TCR specificity in
specifying the DN TCRab IEL fate in the
thymus.
Unlike conventional IEL subsets, DN
TCRab IELs possess a TCR repertoire
skewed toward self-reactivity (Cheroutre
et al., 2011). They exhibit markers of anti-
gen experience in the gut, including cell
surface expression of CD8aa. For this
reason, DN TCRab IELs have been previ-
ously referred to as CD8aa TCRab IELs.
Despite their potential self-reactivity and
partially activated phenotype, DN TCRb
IELs are not destructive to healthy self-tis-
sues and have even been shown to play a
protective role in an induced model of co-
litis (Poussier et al., 2002). However, a
specific function for these cells has not
been defined.
The development and origins of DN
TCRab IELs are a topic of longstandingdebate, with some studies suggesting an
extrathymic pathway of development
(Cheroutre et al., 2011; Rocha 2007).
Alternately, it has been postulated that
DN TCRab IEL precursors, which have
been identified in the thymus, are directed
toward this alternative T cell fate following
the recognition of self-ligands in the
thymus (Gangadharan et al., 2006; Leish-
man et al., 2002). However, the specific
self-ligands of DN TCRab IELs remain un-
identified, as well as the factors driving
differentiation of this enigmatic subset of
T cells.
In this issue of Immunity, Mayans et al.
and McDonald et al. utilize TCRs cloned
from endogenous DN TCRab IELs to
explore the origins, development, and
major histocompatibility complex (MHC)
specificity of these cells. Strikingly, when
these TCRs were ectopically expressed
in mouse hematopoietic progenitor cells,
the vast majority of the resulting periph-
eral T cells localized to the epithelium of
the small intestine and had a phenotype
characteristic of DN TCRab IELs found
in the intestine of wild-typemice, whereas
very few conventional T cells were
observed. These findings demonstrate
that TCR specificity plays a pivotal role
in directing differentiation to the DN
TCRab IEL fate.
Mayans et al. and McDonald et al. also
explore the MHC specificity of DN TCRab
IELs. Both groups report clones restricted
to classical MHC I molecules, while
McDonald et al. additionally identify a
clone restricted to MHC II and Mayans
et al. identify several clones restricted to
unidentified unconventional MHC I mole-
cules. DN TCRab IELs have been previ-
ously reported to express an oligoclonal
TCR repertoire (Regnault et al., 1994).
However, the broad range of reactivityImmunity 41observed in these studies distinguishes
DN TCRab IELs from other innate-like
TCRab lymphocytes expressing oligoclo-
nal TCR repertoires such as NKT cells and
MAIT cells (Stritesky et al., 2012). Rather,
DN TCRab IELs appear to express a truly
polyclonal repertoire that can be masked
due to clonal expansions in the gut.
These studies also contribute to our un-
derstanding of the development of DN
TCRab IELs, providing the first direct evi-
dence that DN TCRab IELs develop in
response to self-reactivity to MHC in the
thymus. The majority of developing thy-
mocytes in mice expressing a TCR
derived from a DN TCRab IEL consisted
of CD4loCD8lo (DP dull) thymocytes that
expressed high amounts of TCR activa-
tion markers, a population previously
associated with self-reactivity and nega-
tive selection. McDonald and colleagues
demonstrate that this DP dull population
is enriched for thymocytes expressing
Bim and active caspase-3, suggesting
that DN TCRab IELs overlap in TCR spec-
ificity with thymocytes undergoing nega-
tive selection. Indeed, the numbers of
DN TCRab IELs, as well as DP dull thymo-
cytes, were increased in animals with
impaired negative selection. Furthermore,
when the authors cloned a TCR from
a thymocyte within this ‘‘negatively se-
lecting’’ population and ectopically ex-
pressed it in T cell progenitors, the result-
ing TCR monoclonal mouse exhibited a
phenotype identical to that of mice mono-
clonally expressing TCRs cloned from DN
TCRab IELs. These data provide unam-
biguous support for the idea that DN
TCRab IELs develop as a result of strong
recognition of self-ligands in the thymus.
There is a growing appreciation that
TCR reactivity to self does not invariably
lead to negative selection but can also, August 21, 2014 ª2014 Elsevier Inc. 167
Figure 1. Thymic Selection of Unconventional Intraepithelial
Lymphocytes
Intestinal intraepithelial lymphocytes consist of both conventional TCRab+
CD4+ or CD8ab+, and unconventional populations of TCRab+CD8b or
TCRgd+CD8b T cells. While conventional CD8ab+ and CD4+ IELs recognize
polymorphic classical MHC-1 and MHC-2 molecules, respectively, TCRab+
CD8b (DN TCRab IELs) can recognize a variety of different MHC molecules
including nonclassical MHC-1 and classical MHC-1 with agonist or TAP inde-
pendent peptides orMHC-2. Following strong recognition of self-ligands in the
thymus, T cell precursors expressing abTCR derived from DN TCRab IELs are
either eliminated by negative selection or undergo agonist selection to give
rise to gut-homing IELs. Lower right shows Venn diagrams illustrating the
overlap in TCR repertoire for positive selection, negative selection, and agonist
selection of nTregs and DN TCRab IELs in the thymus.
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alternative T cell fates, such
as natural Tregs (nTregs)
(Stritesky et al., 2012). DN
TCRab IELs now join the list
of other T cell subsets gener-
ated by agonist selection in
the thymus. However, unlike
nTregs, whose TCR reper-
toire overlaps substantially
with that of conventional
CD4 T cells (Hsieh et al.,
2012), there does not appear
to be significant overlap be-
tween the TCRs that mediate
selection of DN TCRab IELs
and conventional T cells
(Figure 1; Mayans et al.,
2014; McDonald et al.,
2014). This lack of overlap
might reflect the distinct na-
ture of some of the selecting
ligands for DN TCRab IELs,
i.e., nonclassical MHC. How-
ever, given that high-affinity
self-peptides and classical
MHC can also drive DN
TCRab IEL development
(Leishman et al., 2002), it
seems likely that the amount
of self-reactivity required for
DN TCRab IEL development
is substantially higher thanthat required for the development of
nTregs (Figure 1).
While the current studies do not
directly address the function of DN
TCRab IELs, they do provide some
intriguing hints. For example, Mayans
et al. provide evidence that some DN
TCRab IELs recognize MHC-I peptide
complexes that form in the absence of
transporter associated with antigen pro-
cessing (TAP), a critical component of
the normal antigen-processing pathway.
Viruses and cellular transformation can
interfere with antigen processing, result-
ing in the presentation of an altered
repertoire of self-peptides, leading Ma-
yans et al. to speculate that DN TCRab168 Immunity 41, August 21, 2014 ª2014 ElsIELs might play a role in sensing infected
or transformed cells. On the other hand,
rather than responding to diseased or
altered cells, DN TCRab IELs might
detect self-ligands on healthy cells, as
previously suggested for skin gdT cells
(Chodaczek et al., 2012). These signals
could serve to maintain these cells in a
quiescent state or even promote a regu-
latory phenotype. Disease or stress could
modulate DN TCRab IEL activity via
altered presentation of self-ligand, and/
or altered amounts of natural killer (NK)
ligands, whose receptors are prevalent
on the surface of DN TCRab IELs. The
broad range of MHC reactivity revealed
in the studies presented here suggestsevier Inc.that this unique T cell sub-
set is not homogeneous
and could include T cell
clones with varying roles and
mechanisms of activation.
Although much remains to
be learned, the studies pre-
sented here provide impor-
tant information and valuable
tools that will undoubtedly
be instrumental in future in-
vestigations aimed at under-
standing how DN TCRab
IELs develop and how they
contribute to tolerance and
immunity in the gut.REFERENCES
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